Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of INS068 vs Insulin Glargine in T2DM Not Controlled with OADs
NCT05699408Phase 3Completed
- Sponsor
- Hengrui
- Start
- Mar 2023
- Primary completion
- Nov 2024
- Modality
- Peptides, Insulin and Analogs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin sudelidec in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Hengrui. Primary endpoint: Change in Glycated Hemoglobin at 26 weeks. Started Mar 2023; status: completed.
02
Drugs
insulin sudelidec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05699408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05699408.